Pharmafile Logo
Pharmafocus logo
Advanced Search
fda2outsideweb

FDA greenlights Nebriva’s Xenleta for community-acquired bacterial pneumonia

August 20, 2019
Manufacturing and Production, Sales and Marketing FDA, Nabriva, US, Xenleta, pharma, pneumonia

The FDA has awarded approval in the US to Nebriva Therapeutics’ Xenleta (lefamulin) for the treatment of adult patients with …

News
bacteria-3662695_960_720

Drop in prescriptions for antibiotic leads to fewer cases of superbug in Wales

August 20, 2019
Manufacturing and Production AMR, Antibiotics, C difficile, C. difficile, pharma, superbug

Cuts to the number of prescriptions for antibiotics have led to a drop in the number of cases of the …

News
733px-reduction_gear

Finding the needle in the haystack of rare disease

August 19, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Genomenon, Rare Genomics Institute, pharma, rare disease

Through the use of Genomenon’s AI-driven Mastermind Genomic Search Engine, the Rare Genomics Institute succeeded where a leading genetics laboratory …

Feature
celgene_1_02

Celgene’s Inrebic becomes second FDA-approved therapy for rare bone marrow disorder

August 19, 2019
Sales and Marketing Cancer, Cerlgene, FDA, Inrebic, pharma, rare disease

Celgene is celebrating the approval in the US of its Janus kinase (JAK) 2 inhibitor Inrebic (fedratinib) in the treatment …

News
brexit_predictions

British and American healthcare professionals predict further delays to Brexit as Europeans expect no-deal

August 19, 2019
Sales and Marketing EU, UK, US, brexit, brexit delay, healthcare, no-deal, pharma

The majority of healthcare professionals in Europe, Britain and America think Brexit will happen. However they do not believe that …

News
abbvie_0

AbbVie scoops up FDA approval for Rinvoq in moderately to severely active rheumatoid arthritis

August 19, 2019
Sales and Marketing AbbVie, FDA, Rinvoq, pharma, rheumatoid arthritis

The FDA has awarded marketing authorisation to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderately to severely active rheumatoid arthritis, …

News
boris_johnson

UK Government calls on social media companies to fight misinformation surrounding vaccines

August 19, 2019
Sales and Marketing MMR, anti-vaxxers, measles, pharma, vaccination, vaccines

Boris Johnson has called on social media companies to come together to discuss ways in which they can promote accurate …

News
novartis_outside_1

Novartis exec sold off shares before Zolgensma data scandal was revealed

August 19, 2019
Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market

An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …

News

Roche’s cancer drug Rozlytrek scores double approval from FDA

August 16, 2019
Medical Communications Cancer, Roche, Rozlytrek, lung cancer, oncology

The FDA has approved Roche’s Rozlytrek (entrectinib) as a treatment for adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). …

News
cannabis-2152604_960_720

Hundreds of patients turn to private cannabis clinics in UK

August 16, 2019
Medical Communications Marijuana, NHS, UK, cannabis, medicinal cannabis, pharma

Hundreds of people have turned to private clinics, in an effort to gain access to medicinal cannabis in the UK, …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma

Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …

News

Pfizer recall two batches of migraine drug Relpax

August 16, 2019
Medical Communications FDA, Pfizer, Relpax, migraine, pharma, recall

Pfizer has recalled two lots of its migraine drug Relpax over concerns about microbiological contamination. In a statement on the …

News
ipos0_l

Regeneron invest $800 million into New York facilities

August 15, 2019
Medical Communications East Greenbush, New York, Regeneron, pharma

Regeneron is investing $800 million into its New York production facilities. The firm is planning to build a four story …

News
regeneron

Regeneron therapy halves LDL cholesterol levels in rare genetic condition

August 15, 2019
Research and Development Regeneron, evinacumab, pharma, rare disease

Regeneron has reported a strong showing for its investigational angiopoietin-like 3 (ANGPTL3) antibody evinacumab in the treatment of the rare …

News
lilly_building_with_american_flag_web

Lilly’s Taltz beats Janssen’s Tremfya at Phase 4 in plaque psoriasis

August 15, 2019
Research and Development Eli Lilly, Taltz, Tremfya, pharma, psoriasis

Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s …

News
28246711066_52e38bc591_z

Britain call on companies to bid for 24 hour Brexit medicines shipping service contract

August 15, 2019
Business Services, Sales and Marketing UK, brexit, britain, medicines, pharma

The British Government is calling on logistics companies to bid for a £25 million contract to run express freight containers …

News

FDA approve new drug for treatment-resistant TB

August 15, 2019
Research and Development FDA, TB, US, pharma, pretomanid, tuberculosis

The US FDA has approved BPaL, the TB Alliance’s treatment for drug-resistant tuberculosis (TB). The US regulator gave the go-ahead …

News

Executive shake-up at Novartis after Zolgensma data scandal

August 14, 2019
Business Services

The AveXis executives that oversaw the marketing application for Zolgensma, the $2.1 million gene therapy at the centre of the …

News
lynparza

Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations

August 14, 2019
Research and Development AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …

News
janssen_latest_logo_on_sign_closer

Janssen chalks up two more indications in Europe for Imbruvica combo therapies

August 14, 2019
Research and Development, Sales and Marketing Europe, Janssen, chronic lymphocytic leukaemia, imbruvica, pharma

Janssen’s has secured a label expansion from the European Commission for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), approving …

News
The Gateway to Local Adoption Series

Latest content

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026

Accord Healthcare appoints Paul Burden as Associate Vice President and Country Head UK

February 2, 2026

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026